Efficacy and Safety of Adjunctive Oral Ziprasidone for Acute Treatment of Depression in Patients With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To assess efficacy and safety of adjunctive ziprasidone in subjects with bipolar depression treated with lithium, lamotrigine, or valproate. METHOD: 298 adult outpatients with bipolar I disorder (DSM-IV criteria) were randomized to receive ziprasidone, 20-80 mg twice a day, or placebo twice a day for 6 weeks plus their preexisting mood stabilizer. The primary efficacy variable was change in Montgomery-Asberg Depression Rating Scale (MADRS) total scores from baseline to 6 weeks. The key secondary efficacy endpoint was change from baseline to week 6 in Clinical Global Impressions-Severity (CGI-S) scores. Computer-administered assessments for diagnostic confidence were included for quality control and to evaluate study performance. The study was conducted between October 2007 and December 2008. RESULTS: The mean ± SD daily dose of ziprasidone was 89.8 ± 29.1 mg. Least squares mean ± standard error changes from baseline to week 6 on MADRS total score for ziprasidone and placebo treatment groups were -13.2 ± 1.2 and -12.9 ± 1.1, respectively, with a 2-sided P value of .792. There was no significant difference on the key secondary variable (CGI-S). Adjunctive ziprasidone was well tolerated. Poor quality ratings at baseline were associated with a trend for better improvement on placebo than ziprasidone. Among 43 placebo-treated subjects with poor baseline quality ratings, 29 (67.4%) had baseline MADRS scores > 10 points higher on the computer-administered assessment than the MADRS administered by the site-based rater. The response favoring placebo over ziprasidone observed in this subgroup suggests that poor signal detection in some clinical trials can be a consequence of "subject inflation" as well as "rater inflation." CONCLUSIONS: Adjunctive ziprasidone treatment failed to separate from mood stabilizer alone on primary and secondary endpoints. Possible contributions to this result include enrollment of a substantial number of subjects with low diagnostic confidence, low quality ratings on the MADRS, and overzealous reporting of symptoms by subjects. TRIAL REGISTRATION: clinical trials.gov Identifier: NCT00483548.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ziprasidone monotherapy or adjunctive therapy (level 1 negative),242, 294 lamotrigine in combination with folic acid (level 2 negative),251 and mifepristone (adjunctive) (Leve 2 negative)295 are also not recommended due to evidence for lack of antidepressant efficacy (Table 15).”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070984 · Cited by 341
Self-citationLoebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070985 · Cited by 293
Earley, W. R., Burgess, M. V., Khan, B., Rekeda, L., Suppes, T., Tohen, M., & Calabrese, J. R. (2020) · Bipolar Disorders · doi:10.1111/bdi.12852 · Cited by 247
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Fountoulakis, K. Ν., Kasper, S. F., Andreassen, O. A., Blier, P., Okasha, A., Severus, E., Versiani, M., Tandon, R., Möller, H., & Vieta, E. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0323-x · Cited by 149
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Tohen, M., McDonnell, D. P., Case, M., Kanba, S., Ha, K., Fang, Y. R., Katagiri, H., & Gomez, J.-C. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.108357 · Cited by 128
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Calabrese, J. R., Ketter, T. A., Youakim, J. M., Tiller, J. M., Yang, R., & Frye, M. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05900gry · Cited by 116
Antidepressants in bipolar depression: An enduring controversy
Gitlin, M. J. (2018) · International Journal of Bipolar Disorders · doi:10.1186/s40345-018-0133-9 · Cited by 116
Fountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis
Vieta, E., & Valentí, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0073-y · Cited by 104
Interactions between antiepileptics and second-generation antipsychotics
de León, J., Santoro, V., D’Arrigo, C., & Spina, E. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.660918 · Cited by 85
Yatham, L. N., Vieta, E., Goodwin, G. M., Bourin, M., de Bodinat, C., Laredo, J., & Calabrese, J. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.147587 · Cited by 79
Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz064 · Cited by 77
Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions
Elsayed, O. H., Ercis, M., Pahwa, M., & Singh, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s273503 · Cited by 75
Patkar, A., Gilmer, W., Pae, C.-U., Vöhringer, P. A., Ziffra, M., Pirok, E., Mulligan, M., Filkowski, M. M., Whitham, E. A., Holtzman, N. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034757 · Cited by 73
Ketter, T. A., Sarma, K., Silva, R., Kroger, H., Cucchiaro, J., & Loebel, A. (2016) · Depression and Anxiety · doi:10.1002/da.22479 · Cited by 69
Suppes, T., Kroger, H., Pikalov, A., & Loebel, A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.012 · Cited by 65
Managing the side effects associated with commonly used treatments for bipolar depression
Kemp, D. E. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70007-2 · Cited by 62
Porter, R., Bourke, C., Carter, J. D., Douglas, K. M., McIntosh, V. V. W., Jordan, J., Joyce, P. R., & Frampton, C. M. (2015) · Psychological Medicine · doi:10.1017/s0033291715001907 · Cited by 55
Impact of psychotropic drugs on suicide and suicidal behaviors
Yerevanian, B. I., & Choi, Y. M. (2013) · Bipolar Disorders · doi:10.1111/bdi.12098 · Cited by 51
Balancing benefits and harms of treatments for acute bipolar depression
Ketter, T. A., Miller, S., Dell'Osso, B., Calabrese, J. R., Frye, M. A., & Citrome, L. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70006-0 · Cited by 47
Tohen, M. F., Katagiri, H., Fujikoshi, S., & Kanba, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.022 · Cited by 47
Polypharmacy and bipolar disorder: what's personality got to do with it?
Sachs, G. S., Peters, A. T., Sylvia, L., & Grunze, H. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000953 · Cited by 45
Self-citationAkathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence
Chow, C. L., Kadouh, N. K., Bostwick, J. R., & VandenBerg, A. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2404 · Cited by 40
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder
Ketter, T. A., Yang, R., & Frye, M. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.012 · Cited by 40
Treatment of bipolar depression: making sensible decisions
Citrome, L. (2014) · CNS Spectrums · doi:10.1017/s109285291400056x · Cited by 38
Current landscape, unmet needs, and future directions for treatment of bipolar depression
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70005-9 · Cited by 36
Evidence review and clinical guidance for the use of ziprasidone in Canada
Gardner, D. M., Murphy, A. L., Kutcher, S., Beaulieu, S., Carandang, C. G., Labelle, A., Lalonde, P., MALLA, A. K., Milliken, H., O’Donovan, C., et al. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-1 · Cited by 32
Srivastava, S., & Ketter, T. A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.020 · Cited by 31
Frye, M. A., Amchin, J., Bauer, M., Adler, C., Yang, R., & Ketter, T. A. (2015) · International Journal of Bipolar Disorders · doi:10.1186/s40345-015-0034-0 · Cited by 30
Köhler, S., Gaus, S., & Bschor, T. (2014) · Pharmacopsychiatry · doi:10.1055/s-0033-1364004 · Cited by 29
Galling, B., Garcia, M. A., Osuchukwu, U., Hagi, K., & Correll, C. U. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1053457 · Cited by 27
Relationship between placebo response rate and clinical trial outcome in bipolar depression
Iovieno, N., Nierenberg, A. A., Parkin, S. R., Kim, D. J. H., Walker, R. S. W., Fava, M., & Papakostas, G. I. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.12.016 · Cited by 27
Katagiri, H., Tohen, M. F., McDonnell, D., Fujikoshi, S., Case, M. G., Kanba, S., Takahashi, M., & Gomez, J.-C. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-138 · Cited by 25
The development of lurasidone for bipolar depression
Loebel, A. D., Xu, J., Hsu, J., Cucchiaro, J. B., & Pikalov, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12965 · Cited by 23
Bartoli, F., Dell’Osso, B. M., Crocamo, C., Fiorillo, A., Ketter, T. A., Suppes, T. M., Clerici, M., & Carrà, G. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.12.021 · Cited by 23
An overview of pharmacotherapy for bipolar I disorder
Morsel, A., Morrens, M., & Sabbe, B. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1426746 · Cited by 23
Wang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 23
A systematic review of the evidence for the treatment of acute depression in bipolar I disorder
Cerullo, M. A., & Strakowski, S. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000102 · Cited by 21
Korean Medication Algorithm Project for Bipolar Disorder: third revision
Bahk, W., Woo, Y. S., Lee, J. G., Jeong, J., Kim, M.-D., Sohn, I., Shim, S.-H., Jon, D., Seo, J. S., Min, K. J., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s77838 · Cited by 21
Mandrioli, R., Protti, M., & Mercolini, L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.991713 · Cited by 21
Goldberg, J. F. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190008 · Cited by 20
Maruki, T., Utsumi, T., Takeshima, M., Fujiwara, Y., Matsui, M., Aoki, Y., Toda, H., Watanabe, N., Watanabe, K., & Takaesu, Y. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00271-7 · Cited by 19
Gao, K., Yuan, C., Wu, R., Chen, J., Wang, Z., Fang, Y., & Calabrese, J. R. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1534-0 · Cited by 19
Gao, K., Pappadopulos, E. A., Karayal, O. N., Kolluri, S., & Calabrese, J. R. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182917f3f · Cited by 17
Human Dopamine Transporter Gene: Differential Regulation of 18-kb Haplotypes
Zhao, Y. Y., Xiong, N., Liu, Y., Zhou, Y., Li, N., Qing, H., & Lin, Z. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.141 · Cited by 17
Antipsychotic and anticholinergic drugs
Meltzer, H. Y., & Bobo, W. V. (2020) · doi:10.1093/med/9780198713005.003.0064 · Cited by 16
Cullen, C., Kappelmann, N., Umer, M., Abdolizadeh, A., Husain, M. O., Bonato, S., Sharma, G. K., Xue, S., Ortiz, A., Kloiber, S. M., et al. (2021) · Bipolar Disorders · doi:10.1111/bdi.13125 · Cited by 16
Advances in Treatment of Bipolar Disorders
(2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378210 · Cited by 15
Improving Outcomes in Patients With Bipolar Depression: A Comprehensive Review
Nierenberg, A. A., McIntyre, R. S., & Sachs, G. S. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13091ip1 · Cited by 14
Self-citationAntidepressants in Bipolar Depression: An Enduring Controversy
Gitlin, M. J. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17306 · Cited by 12
Loebel, A., Siu, C., Rajagopalan, K., Pikalov, A., Cucchiaro, J., & Ketter, T. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.033 · Cited by 11
“In contrast, the other atypical antipsychotics aripiprazole and ziprasidone did not differentiate from placebo in randomized acute bipolar I depression trials (Thase et al., 2008; Lombardo et al., 2012; Sachs et al., 2011).”
ResultPharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach
Muneer, A. (2016) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2016.37.3.137 · Cited by 11
Kam, K.-Y., Jalin, A. M. A. A., Choi, Y. W., Kaengkan, P., Park, S. W., Kim, Y., & Kang, S. G. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.05.010 · Cited by 10
Álamo, C., Lopez-Munoz, F. J., & García‐García, P. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915741 · Cited by 10
Bipolar Depression: An Evidence-Based Approach
Baldassano, C. F., Hosey, A., & Coello, J. A. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0238-7 · Cited by 9
Köhler, S., Bauer, M., & Bschor, T. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3919-0 · Cited by 8
Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology
Potter, W. Z., Mallinckrodt, C. H., & Detke, M. J. (2014) · Pharmaceutical Medicine · doi:10.1007/s40290-014-0052-8 · Cited by 8
Gao, K., Kemp, D. E., Wu, R., & Calabrese, J. R. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch105 · Cited by 7
The Treatment of Bipolar Depression: Current Status and Future Perspectives
Jelen, L. A., & Young, A. H. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00200-x · Cited by 7
Liu, W., Wang, S.-S., Lu, W., Cheng, Z., & Jiang, N. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1592-8 · Cited by 6
Tocco, M., & Mao, Y. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001850 · Cited by 4
İki uçlu depresyonun farmakolojik tedavisinde yenilikler
Bez, Y. (2013) · Journal of Mood Disorders · Cited by 4
Geerling, B., Kraiss, J. T., Kelders, S. M., Stevens, A. W. M. M., Kupka, R., & Bohlmeijer, E. T. (2019) · Bipolar Disorders · doi:10.1111/bdi.12746 · Cited by 4
Antipsicóticos para la depresión bipolar: la paradoja
Pacchiarotti, I. (2015) · Psiquiatría Biológica · doi:10.1016/s1134-5934(15)30007-5 · Cited by 3
Fountoulakis, K. N. (2014) · Springer eBooks · doi:10.1007/978-3-642-37216-2_16 · Cited by 3
Evidence Based Combination Therapy for Bipolar Disorder
Magiria, S., Siamouli, M., Gonda, X., Iacovides, A., & Fountoulakis, K. Ν. (2012) · Springer eBooks · doi:10.1007/978-94-007-5799-8_9 · Cited by 3
Ziprasidone as Adjunctive Therapy in Severe Bipolar Patients Treated with Clozapine
Bartolommei, N., Casamassima, F., Pensabene, L., Luchini, F., Benvenuti, A., Paolo, A. D., Cosentino, L., Mauri, M., & Lattanzi, L. (2014) · ISRN Psychiatry · doi:10.1155/2014/904829 · Cited by 3
Pharmacological Treatment of the Maintenance Phase of Bipolar Depression: Efficacy and Side Effects
Gao, K., Wu, R., & Calabrese, J. R. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_10 · Cited by 3
The role of antipsychotics and mood stabilizers in the treatment of bipolar disorder
Correll, C. U. (2011) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 2
Andrade, C. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13f08410 · Cited by 2
Pharmacological Treatment Strategies for Acute Bipolar Depression
Kim, S. J. (2018) · 신경정신의학 · doi:10.4306/jknpa.2018.57.4.287 · Cited by 2
Are (Some) Antipsychotics Depressogenic in Bipolar Disorder?
Goldberg, J. F. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20com13284 · Cited by 1
Medications for Bipolar Disorder
Mitchell, P. B. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_135 · Cited by 1
Kessing, L. V. (2025) · Danish Medical Journal · doi:10.61409/a07250539 · Cited by 1
The Role of Atypical Antipsychotic Therapy for Patients with Treatment- Resistant Bipolar Depression
Shah, A. S. (2014) · African Journal of Psychiatry · doi:10.4172/1994-8220.1000150 · Cited by 1
The use of atypical antipsychotic drugs in Bipolar II disorder
Vieta, E., & Cruz, N. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003315.013 · Cited by 1
Clinical models for managing Bipolar II disorder: model 2
Ketter, T. A., & Wang, P. W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003315.019 · Cited by 1
Behandlung bipolarer Störungen
Grunze, H., Grunze, A., & Born, C. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_3 · Cited by 1
Reichelt, L. (2020) · mediaTUM (Technical University of Munich) · Cited by 1
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.004
Alberdi, G., & Manuel, J. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Shah, A. S. (2015) · International Journal of Emergency Mental Health and Human Resilience · doi:10.4172/1522-4821.1000198
What Lamotrigine and Ziprasidone Are Not Good For
Roy‐Byrne, P. (2011) · Journal watch · doi:10.1056/jp201112190000001
Pharmacologic and somatic treatments for bipolar depression
Giner, L., Kelly, S. A., & Oquendo, M. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.007
Chapter 13. Acute and Maintenance Treatment of Bipolar and Related Disorders
Ketter, T. A., Miller, S., & Goldberg, J. F. (2014) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781585625048.gg13
Almalki, Z. S. (2017) · OhioLink ETD Center (Ohio Library and Information Network)
The Use of Antipsychotic Drugs in Bipolar II Disorder
Vieta, E. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108333252.014
Guidelines on Mood Stabilizers
Gfesser, J., & Kittel‐Schneider, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_117-1
Thase, M. E. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003315.030
Guidelines on Mood Stabilizers
Gfesser, J., & Kittel‐Schneider, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_117
Medications for Bipolar Disorder
Mitchell, P. B. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_135-1
(2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378210.fm01
Chapter 2. Treatment of Acute Bipolar Depression
Ketter, T. A., Miller, S., Wang, P. W., & Culver, J. L. (2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378210.lg02
Chapter 6. Treatment of Women With Bipolar Disorder
Ketter, T. A., Rasgon, N., & Vemuri, M. (2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378210.lg06
(2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378210.index
Chapter 7. Treatment of Older Adults With Bipolar Disorder
Ketter, T. A., & Brooks, J. O. (2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615378210.lg07
Metadata
- Authors
- Sachs, G. S., Ice, K. S., Chappell, P. B., Schwartz, J. H., Gurtovaya, O., Vanderburg, D. G., & Kasuba, B.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Sachs, Gary S.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-05-03
- Volume
- 72
- Issue
- 10
- Pages
- 1413-1422
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2011905433
- Cited by
- 101
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 1 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 26 · 2014: 10 · 2013: 16 · 2012: 11
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- ziprasidone, bipolar depression, bipolar I disorder, adjunctive therapy, atypical antipsychotics, mood stabilizers, lithium, lamotrigine, valproic acid, treatment efficacy, drug safety, diagnostic confidence, signal detection
- MeSH terms
- Lamotrigine, Acute Disease, Adolescent, Adult, Aged, Bipolar Disorder, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Lithium, Male, Middle Aged, Piperazines, Serotonin Antagonists, Thiazoles, Triazines, Valproic Acid, Treatment Outcome, Antimanic Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.